HC Wainwright & Co. Maintains Buy on NeuroSense Therapeutics, Raises Price Target to $52
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice TargetStock Split
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
HC Wainwright & Co. analyst Lander Egaña Gorroño maintains NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy and raises the price target from $8 to $52.
HC Wainwright & Co. analyst Lander Egaña Gorroño maintains NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy and raises the price target from $8 to $52.
